Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Provencher

Showing results (91-100 of 109) with videos related to

Pageof 11
Sort By:
BMC Cancer|August 31, 2012
Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancerIsabelle J Létourneau, Michael C J Quinn, Lu-Lin Wang, et al.
Molecular Oncology|February 19, 2013
VGLL3 expression is associated with a tumor suppressor phenotype in epithelial ovarian cancerKaren Gambaro, Michael C J Quinn, Paulina M Wojnarowicz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2019
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 studyU A Matulonis, R Shapira-Frommer, A D Santin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 30, 2017
OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancerD M Provencher, C J Gallagher, W R Parulekar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2011
Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancerBeth Y Karlan, Amit M Oza, Gary E Richardson, et al.
The Lancet. Oncology|June 22, 2014
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trialBradley J Monk, Andrés Poveda, Ignace Vergote, et al.
Gynecologic Oncology|October 20, 2023
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100Jonathan A Ledermann, Ronnie Shapira-Frommer, Alessandro D Santin, et al.
BMC Cancer|March 29, 2018
Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkersCécile Le Page, Kurosh Rahimi, Martin Köbel, et al.
Gynecologic Oncology|August 23, 2016
Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2Bradley J Monk, Andrés Poveda, Ignace Vergote, et al.
Gynecologic Oncology|October 13, 2021
Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancerG E Konecny, A E Wahner Hendrickson, T M Davidson, et al.
Pageof 11

Showing results (91-100 of 109) with videos related to

Sort By:
Pageof 11
BMC Cancer|August 31, 2012
Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancerIsabelle J Létourneau, Michael C J Quinn, Lu-Lin Wang, et al.
Molecular Oncology|February 19, 2013
VGLL3 expression is associated with a tumor suppressor phenotype in epithelial ovarian cancerKaren Gambaro, Michael C J Quinn, Paulina M Wojnarowicz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2019
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 studyU A Matulonis, R Shapira-Frommer, A D Santin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 30, 2017
OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancerD M Provencher, C J Gallagher, W R Parulekar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2011
Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancerBeth Y Karlan, Amit M Oza, Gary E Richardson, et al.
The Lancet. Oncology|June 22, 2014
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trialBradley J Monk, Andrés Poveda, Ignace Vergote, et al.
Gynecologic Oncology|October 20, 2023
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100Jonathan A Ledermann, Ronnie Shapira-Frommer, Alessandro D Santin, et al.
BMC Cancer|March 29, 2018
Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkersCécile Le Page, Kurosh Rahimi, Martin Köbel, et al.
Gynecologic Oncology|August 23, 2016
Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2Bradley J Monk, Andrés Poveda, Ignace Vergote, et al.
Gynecologic Oncology|October 13, 2021
Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancerG E Konecny, A E Wahner Hendrickson, T M Davidson, et al.
Pageof 11